147 related articles for article (PubMed ID: 10764846)
1. Combining sulfonylureas and other oral agents.
Riddle M
Am J Med; 2000 Apr; 108 Suppl 6a():15S-22S. PubMed ID: 10764846
[TBL] [Abstract][Full Text] [Related]
2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
3. Treating diabetes using oral agents.
Malik T; Trence DL
Prim Care; 2003 Sep; 30(3):527-41. PubMed ID: 14692199
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Combining insulin and oral agents.
Buse J
Am J Med; 2000 Apr; 108 Suppl 6a():23S-32S. PubMed ID: 10764847
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic therapy for type 2 diabetes mellitus.
DeFronzo RA
Ann Intern Med; 1999 Aug; 131(4):281-303. PubMed ID: 10454950
[TBL] [Abstract][Full Text] [Related]
7. Oral combination therapy for type 2 diabetes.
Charpentier G
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989
[TBL] [Abstract][Full Text] [Related]
8. [Fixed-dose combination].
Nagai Y
Nihon Rinsho; 2015 Mar; 73(3):465-9. PubMed ID: 25812374
[TBL] [Abstract][Full Text] [Related]
9. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
[TBL] [Abstract][Full Text] [Related]
10. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Raskin P
Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
[TBL] [Abstract][Full Text] [Related]
11. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
[TBL] [Abstract][Full Text] [Related]
13. [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].
Nauck MA; Matthaei S
Dtsch Med Wochenschr; 2005 Apr; 130(17):1091-6. PubMed ID: 15841424
[No Abstract] [Full Text] [Related]
14. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
[TBL] [Abstract][Full Text] [Related]
15. [Used of oral antidiabetic agents in pediatric patients - own observations].
Stańczyk J; Otto-Buczkowska E; Jarosz-Chobot P; Nowowiejska B
Endokrynol Pol; 2008; 59(5):434-43. PubMed ID: 18979454
[TBL] [Abstract][Full Text] [Related]
16. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
17. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
18. An overview of metformin in the treatment of type 2 diabetes mellitus.
Davidson MB; Peters AL
Am J Med; 1997 Jan; 102(1):99-110. PubMed ID: 9209206
[TBL] [Abstract][Full Text] [Related]
19. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L
Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404
[No Abstract] [Full Text] [Related]
20. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
Rybka J
Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
